Slide 1: 2025 Q3 Report
Sustainable healthcare for a new generation 2025 Q3 Report October 20th, 2025
Slide 2: Disclaimer
Disclaimer THIS PERESNTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. T
Slide 3: Topics for today
Commercial progress update Customer impact driving word-of-mouth Topics for Priorities to close out 2025 today Financial update Respond to your questions
Slide 4: Key messages for today
Key messages for today Q3 saw record consumables demand as installation was completed 1 for six instruments sold in H1 2025 Commercial pipeline continues to grow robustly in US, EMEA 2 and with new leads across Asia and Latin America Anticipate a strong close to the year as contracting processes 3 c
Slide 5: Q-linea revolutionising AST | Flagship ASTar platform designed to save lives
Q-linea revolutionising AST | Flagship ASTar platform designed to save lives Fully-automated, random 1st access platform Minutes hands-on time ~2 simple interface, load-and-go system Comprehensive menu High reproducibility Hours turn-around time ~6 High throughput with 12 samples in parallel s
Slide 6: A new standard of care | Critical patient testing moving to rapid AST
A new standard of care | Critical patient testing moving to rapid AST Clinical value Current standard of care Emerging new standard of care of information Colony-based AST Positive Blood Culture AST Whole Blood AST 5 – 7m blood infection tests Clinically- 5 – 10m critical non-blood AST urgent te
Slide 7: Sales development | Continued progress on installed base growth
Sales development | Continued progress on installed base growth ASTar units contracted for routine clinical Three additional ASTar contracts in US and Italy use at end-of-period Record consumables demand driven by six systems 30 going live in Q3 More than 15 countries now with ongoing ASTar 17
Slide 8: Scientific voice | Partnerships and events to maintain Q-linea's leadership
Scientific voice | Partnerships and events to maintain Q-linea’s leadership Publications and presentations at major customer events ADLM 2025 in Chicago, IL SWACM 2025 in Dallas, TX NACMID 2025 in Nashua, NH IBMS 2025 in Birmingham, UK Demonstrating results from ASTar in clinical use Partn
Slide 9: Voice-of-customer | Evidence presented by customers in UK and US
Voice-of-customer | Evidence presented by customers in UK and US Summary of poster presentation made by Jennifer Monkhouse at IBMS 2025 in Birmingham, UK Savings in Sepsis | UK lab seeing benefits from ASTar for patients and NHS The Implementation and Impact of the Q-linea ASTar System within Mersey
Slide 10: Closing 2025 strong | Priorities for Q4 2025
Closing 2025 strong | Priorities for Q4 2025 Commercial Convert ongoing contracting discussions in US and EMEA: drive to 30 ASTars priorities Support Pheno users approaching Q-linea for conversions to maintain rapid AST in lab Establish first evaluations for ASTar in Asia and Latin America C
Slide 11: Financial highlights | Third quarter 2025
Financial highlights | Third quarter 2025 REVENUES Net sales in the quarter of SEK 3.5 million, record month in September for consumables (recurring income), will continue to increase as the installed base increases Net sales SEK 8.2 million for the period Jan – September 2025, approx. 370% growth o
Slide 12: OPEX development | 2023 – 2025Q3
OPEX development | 2023 – 2025Q3 Personnel expenses + Other external costs A clear shift with less personnel and expenses directly 25 000 involved in R&D, and an increase of sales, sales support & marketing resources 20 000 15 000 Cost efficiency and customer focused going forward! 10 000 No.
Slide 13: Events to come | Rights issue
Events to come| Rights issue Oct 21: Extraordinary general meeting, approval of the board of directors’ resolution on the Rights Issue Oct 21: Last day of trading in the Company’s shares including the right to receive subscription rights Oct 22: Publishing of prospectus Oct 22: First day of
Slide 14: Future financing
Future financing Secured financing: Cash at hand 30 of September 2025: SEK 42,6 million Rights issue announced 18 September SEK 220 million (after netting of loan and transaction costs) --- 85.6% guaranted SEK 266 million (after netting of loan and transaction costs) --- 100% Total secured financi
Slide 15: Thank you!
Thank Questions? you!